Who owns LYRA THERAPEUTICS INC?
- Ticker: LYRA
- CUSIP Number: 55234l105
Tip: Access positions for across all investors
Analyze quarterly positions in Lyra Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Lyra Therapeutics stock
Who bought or sold LYRA THERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Perceptive Advisors | 13M | $79M | 0% | Mar 2024 |
|
| Citadel Advisors | 4.3M | $27M | 52% | Mar 2024 |
|
| Nantahala Capital Management | 2.8M | $18M | -30% | Mar 2024 |
|
| Samsara BioCapital | 2.8M | $17M | 0% | Mar 2024 |
|
| Point72 Asset Management | 2.7M | $17M | -9% | Mar 2024 |
|
| VR Adviser | 2.6M | $16M | 0% | Mar 2024 |
|
| Vanguard Group | 1.5M | $9.2M | 38% | Mar 2024 |
|
| Pura Vida Investments | 1.4M | $8.8M | 0% | Mar 2024 |
|
| Rosalind Advisors | 1.1M | $7.1M | -39% | Mar 2024 |
|
| Ikarian Capital | 1.1M | $6.6M | -16% | Mar 2024 |
|
| Tri Locum Partners | 979k | $6.1M | 100% | Mar 2024 |
|
| Verition Fund Management | 768k | $4.8M | 100% | Mar 2024 |
|
| Laurion Capital Management | 748k | $4.7M | 1663% | Mar 2024 |
|
| Woodline Partners | 677k | $4.2M | 100% | Mar 2024 |
|
| Parkman Healthcare Partners | 642k | $4.0M | 3% | Mar 2024 |
|
| Ensign Peak Advisors | 591k | $3.7M | 96% | Mar 2024 |
|
| Walleye Trading Advisors | 528k | $3.3M | 3419% | Mar 2024 |
|
| Millennium Management | 406k | $2.5M | 25% | Mar 2024 |
|
| Susquehanna International | 394k | $2.4M | 142% | Mar 2024 |
|
| Geode Capital Management | 359k | $2.2M | 16% | Mar 2024 |
|
| Schonfeld Strategic Advisors | 357k | $2.2M | 757% | Mar 2024 |
|
| Goldman Sachs Group | 335k | $2.1M | 2462% | Mar 2024 |
|
| Hudson Bay Capital Management | 250k | $1.6M | 100% | Mar 2024 |
|
| Alyeska Investment Group | 241k | $1.5M | 0% | Mar 2024 |
|
| Boothbay Fund Management | 233k | $1.4M | -1% | Mar 2024 |
|
| Dimensional Fund Advisors | 191k | $1.2M | 70% | Mar 2024 |
|
| Two Sigma Investments | 184k | $1.1M | 39% | Mar 2024 |
|
| Bank of America Corporation | 160k | $993k | 10% | Mar 2024 |
|
| Jane Street | 158k | $981k | 102% | Mar 2024 |
|
| BlackRock | 152k | $945k | 220% | Mar 2024 |
|
| Superstring Capital Management | 145k | $904k | 100% | Mar 2024 |
|
| Two Sigma Advisers | 144k | $895k | 184% | Mar 2024 |
|
| Qube Research & Technologies | 132k | $820k | 3919% | Mar 2024 |
|
| Clearline Capital | 119k | $741k | 0% | Mar 2024 |
|
| Citigroup | 119k | $739k | -4% | Mar 2024 |
|
| Jpmorgan Chase & Co | 109k | $679k | 230% | Mar 2024 |
|
| Hrt Financial | 99k | $612k | 100% | Mar 2024 |
|
| Man Group | 90k | $562k | 138% | Mar 2024 |
|
| Bridgeway Capital Management | 87k | $540k | -39% | Mar 2024 |
|
| Marathon Trading Investment Management | 67k | $417k | 100% | Mar 2024 |
|
| Morgan Stanley | 64k | $401k | 100% | Mar 2024 |
|
| Northern Trust | 61k | $376k | 6% | Mar 2024 |
|
| Cambridge Investment Research Advisors | 42k | $259k | 100% | Mar 2024 |
|
| Barclays | 33k | $204k | 0% | Mar 2024 |
|
| ExodusPoint Capital Management | 32k | $200k | 100% | Mar 2024 |
|
| Letko, Brosseau & Associates | 32k | $198k | 0% | Mar 2024 |
|
| Balyasny Asset Management | 32k | $196k | 9% | Mar 2024 |
|
| American Century Companies | 26k | $160k | 100% | Mar 2024 |
|
| Occudo Quantitative Strategies | 23k | $142k | 100% | Mar 2024 |
|
| Cubist Systematic Strategies | 21k | $132k | -29% | Mar 2024 |
|
| Y-Intercept | 21k | $128k | 100% | Mar 2024 |
|
| Jump Financial | 17k | $88k | 100% | Dec 2023 |
|
| Springbok Capital Management | 15k | $96k | 100% | Mar 2024 |
|
| Brevan Howard Capital Management | 14k | $87k | 100% | Mar 2024 |
|
| Bank Of Montreal | 14k | $82k | 100% | Mar 2024 |
|
| DLK Investment Management | 12k | $75k | 0% | Mar 2024 |
|
| Squarepoint Ops | 12k | $73k | 100% | Mar 2024 |
|
| Leucadia National Corporation | 11k | $71k | 100% | Mar 2024 |
|
| Engineers Gate Manager | 11k | $67k | 100% | Mar 2024 |
|
| Heritage Wealth Management, Inc./Texas | 10k | $62k | 0% | Mar 2024 |
|
| Tower Research Capital | 8.9k | $56k | 32% | Mar 2024 |
|
| Point72 Asia | 5.7k | $36k | 774% | Mar 2024 |
|
| Advisor Group Holdings | 2.0k | $12k | 0% | Mar 2024 |
|
| Brian McDonald | 1.2k | $7.2k | 0% | Mar 2024 |
|
| Royal Bank of Canada | 654.00 | $4.0k | -80% | Mar 2024 |
|
| Rhumbline Advisers | 296.00 | $1.8k | 0% | Mar 2024 |
|
| Wells Fargo & Company | 251.00 | $1.6k | 2% | Mar 2024 |
|
| Northwestern Mutual Wealth Management Company | 100.00 | $622.000000 | 100% | Mar 2024 |
|
| UBS Group | 18.00 | $111.999600 | -100% | Mar 2024 |
|
Who sold out of Lyra Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Armistice Capital | Sep 2023 | 1.6M | $6.1M |
| 683 Capital Management | Dec 2023 | 70k | $366k |
| Virtu Financial | Sep 2023 | 20k | $77k |
| Bank of New York Mellon | Dec 2023 | 19k | $98k |
| Two Sigma Securities | Dec 2023 | 13k | $67k |
| Simplex Trading | Dec 2023 | 1.2k | $6.0k |
| Group One Trading | Sep 2023 | 200.00 | $782.000000 |